Review period expiry for use of 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated (4-tert-OPnEO)
REACH authorisation expiry of five uses, granted to Octapharma AB, Produktionsgesel schaft Deutschland mbH and Octapharma S.A.S.
EU REACH Authorisation
Review period expiry for use of 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated (4-tert-OPnEO)
REACH authorisation expiry of three uses, granted to SEBIA
Review period expiry for use of 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated (4-tert-OPnEO)
REACH authorisation expiry of one use, granted to Eli Lilly Kinsale Limited
Review period expiry for use of 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated (4-tert-OPnEO)
REACH authorisation expiry of one use, granted to Sanquin Reagents B.V.
Review period expiry for use of 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated (4-tert-OPnEO)
REACH authorisation expiry of one use, granted to Octapharma Pharmazeutika Produktionsgesellschaft m.b.H
European Commission decisions on applications for authorisation
The European Commission has granted 19 authorisations for uses of the following substances (review period expiry dates are in brackets): 4-(1,1,3,3-Tetra methylbutyl)phenol, ethoxylated (4-tert-OPnEO) 5 uses applied for by Octapharma AB and 4 other co-applicants (4 January 2033 and 4 January 2025);…